Is big pharma guiding federal drug policy? Impact of proposed regulations on prices & access to new medicines

In February 2023, Dr. Matthew Herder resigned from the Patented Medicine Prices Review Board (PMPRB), citing the government’s failure to implement critical reforms to lower medicine costs. Health Minister Jean-Yves Duclos has denied any interference, stressing that the PMPRB is politically independent.

Dr. Aslam Anis (Professor and Director Pro Tem, School of Population and Public Health) will explore this impasse, the role of the PMPRB in drug pricing, and the future of pharmaceutical regulation in Canada.

Dr. Aslam Anis is Professor and Director Pro Tem at the UBC School of Population and Public Health. His research area spans across cost effectiveness of AIDS treatments, drug assessments – pharmacoeconomics, health care economics, health regulations, Health economics, rhematoid arthritis, biologic therapies.